GUOLO , Fabio

Last name: GUOLO

First name: Fabio

Email: fabio.guolo@unige.it

Institution: UNIGE

Links

March 30, 2021 (v1)

Publication

Metadata-only

POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA PATIENTS: A SAFE AND EFFECTIVE THERAPY ASSOCIATED WITH EXPANSION AND MATURATION OF NK CELLS

GUOLO, FABIO

Hodgkin Lymphoma (HL) is a B-Cell neoplasia with a favourable outcome in responding patients. However, despite the efficacy of first line therapy about 30% of patients eventually relapse or are refractory (R/R). Recently, the immune checkpoint inhibitor (CI) nivolumab demonstrated good activity in R/R HL patients although the complete response...

Uploaded on: April 14, 2023
2016 (v1)

Publication

Metadata-only

Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia

MINETTO, PAOLA GUOLO, FABIO MIGLINO, MAURIZIO

No description

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

GUOLO, FABIO MINETTO, PAOLA Clavio, Marino

Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3-4 cases per 100,000 people/year. After the first description of the effective cytarabine + antracycline (3+7) induction regimen, in the last 3 decades, no effective targeted drug has been included in the standard treatment of AML. Many efforts...

Uploaded on: April 14, 2023
2018 (v1)

Publication

Metadata-only

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

MINETTO, PAOLA GUOLO, FABIO Clavio, Marino

No description

Uploaded on: April 14, 2023

GUOLO , Fabio

Recent uploads